Lucent Diagnostics, Tempus Collaborate on Blood-Based Alzheimer’s Biomarker Testing

Lucent Diagnostics, a brand of Quanterix Corporation, is partnering with Tempus AI Inc. to expand access to a blood-based biomarker panel aimed at improving Alzheimer’s disease detection.

Under the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, with the LucentAD Complete multi-biomarker blood test becoming available for neurologists to order.

More than 7 million Americans currently live with Alzheimer’s disease, yet only a small fraction are evaluated for eligibility for approved treatments. This collaboration aims to narrow that gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists.

“This collaboration represents an important step toward ensuring blood-based Alzheimer’s biomarker testing becomes part of routine clinical practice—without placing additional burden on providers,” Quanterix CEO Everett Cunningham stated. “By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. As we look to advance precision health through high-sensitivity biomarker innovation, collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions.”

Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and equips providers with actionable insights consistent with clinical guidelines at the point of care. While the Tempus Next Care Gap Program helps identify patients who may benefit from biomarker testing based on established clinical guidelines, clinicians can order LucentAD Complete through existing EHR integrations.

Lucent Diagnostics was created in 2023 to deliver tools that help detect cognitive disease at an earlier stage. Powered by the ultra-sensitive Simoa technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics.